This company listing is no longer active
Eisai (ESAL.Y) Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
ESAL.Y Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥61.51 |
| 52 Week High | JP¥73.90 |
| 52 Week Low | JP¥36.88 |
| Beta | 0.21 |
| 1 Month Change | -7.24% |
| 3 Month Change | 2.28% |
| 1 Year Change | 19.69% |
| 3 Year Change | -28.69% |
| 5 Year Change | 9.25% |
| Change since IPO | 208.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| ESAL.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.4% | -1.1% | -2.0% |
| 1Y | 19.7% | 28.6% | 11.2% |
Return vs Industry: ESAL.Y exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: ESAL.Y exceeded the US Market which returned -12.5% over the past year.
Price Volatility
| ESAL.Y volatility | |
|---|---|
| ESAL.Y Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ESAL.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: ESAL.Y's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,322 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer’s disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma.
Eisai Co., Ltd. Fundamentals Summary
| ESAL.Y fundamental statistics | |
|---|---|
| Market cap | US$17.66b |
| Earnings (TTM) | US$247.68m |
| Revenue (TTM) | US$5.78b |
Is ESAL.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESAL.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥752.50b |
| Cost of Revenue | JP¥187.50b |
| Gross Profit | JP¥565.00b |
| Other Expenses | JP¥532.77b |
| Earnings | JP¥32.23b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 06, 2023
| Earnings per share (EPS) | 112.35 |
| Gross Margin | 75.08% |
| Net Profit Margin | 4.28% |
| Debt/Equity Ratio | 11.2% |
How did ESAL.Y perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/01 02:51 |
| End of Day Share Price | 2023/01/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eisai Co., Ltd. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |